Let's get to Eli Liy here. Surging almost 4% today after a beat and raise uh earnings report thanks to booming demand for its GLP1 drugs zbound in Monjaro. Also an obese obesity Novo Nordisk down 2 and a half% after confirming that it has made an unsolicited bid to acquire Meter better than the offer that Fizer had made last month.Semaphore reporting this afternoon that Fizer is considering a lawsuit against Novo and Metsa over the bid. For more on all of this, Missouo healthcare strategist Jared Holles is ...

On 5 November 2025, Novo Nordisk A/S ( NVO ) will announce its Q3 2025 earnings. Given that I've previously conducted a more detailed , and I think it's fair to say, veryI’ve managed my investments since 1999, gaining perspective across multiple market cycles. With a background in Economics and ongoing CFA certification, my focus is on uncovering mispriced assets that the market has overlooked.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, a ...

On 5 November 2025, Novo Nordisk A/S ( NVO ) will announce its Q3 2025 earnings. Given that I've previously conducted a more detailed , and I think it's fair to say, veryI’ve managed my investments since 1999, gaining perspective across multiple market cycles. With a background in Economics and ongoing CFA certification, my focus is on uncovering mispriced assets that the market has overlooked.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, a ...

Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish drugmaker as it seeks to regain ground in the weight-loss drug market unde... ...

By Maggie Fick LONDON (Reuters) -Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish drugmaker as it seeks to regain ground in the weight-loss drug market under a new CEO and board. Novo, the drugmaker behind blockbuster weight-loss drug Wegovy and diabetes treatment Ozempic, launched a bid on Thursday for Metsera valuing the firm at some $9 billion and crashing Pfizer's deal for the firm announced in September. The move, after No ...

TRENDING: You Don't Have To Dig Far To Cash In On Rare Earths Novo Nordisk (NVO) kicked off a new battle with Pfizer (PFE) on Thursday by making an unsolicited $6.5 billion bid for obesity-focused takeover target, Metsera (MTSR). The bid sent shock waves through Wall Street. "You wouldn't have expected a GLP-1 incumbent to be bidding here," Evercore ISI analyst Umer Raffat said in a report to clients. "But you know what the bigger surprise is? That Novo is basically offering a 50% termination fee." Pfizer a ...

On Thursday, Metsera Inc. (NASDAQ:MTSR) received an unsolicited acquisition proposal from Novo Nordisk A/S (NYSE:NVO).Metsera said the proposal constitutes a “Superior Company Proposal” as defined in Metsera’s existing Merger Agreement with Pfizer Inc (NYSE:PFE).In September, Pfizer agreed to acquire Metsera for $47.50 per share in cash, representing an enterprise value of approximately $4.9 billion.The acquisition brings a portfolio of differentiated oral and injectable incretin, non-incretin, and combinat ...

Metsera此前在9月已同意接受辉瑞最高73亿美元的收购方案。该公司周四表示，在诺和诺德的未经邀请的新报价公开后，认为后者"更 具优势"。诺和诺德——司美格鲁肽（Ozempic）与Wegovy减重药物的制造商——提出以每股56.50美元收购Metsera，对应总股权价值 65亿美元。此外，该交易还包括每股21.25美元的里程碑付款，若公司达到特定临床与监管目标，将再支付25亿美元。 诺和诺德此举在生物科技领域属罕见的主动收购，可能引发竞价战。辉瑞目前有四个工作日可提出更高报价。Metsera表示，辉瑞已告 知公司其"不认为Metsera有权将诺和诺德的报价认定为更优方案"。 整理 | GLP1减重宝典内容团队 丹麦制药巨头诺和诺德（Novo Nordisk）突袭美国制药公司辉瑞（Pfizer）对减重生物科技公司Metsera的收购计划，开出高达90亿美 元的新报价，引发对其遏制竞争的指控。 诺和诺德的举动发生在Doustdar今年8月上任之后。此前，前任CEO Lars Fruergaard Jørgensen因公司股价一年内暴跌逾50%而被罢免。 新任CEO已承诺将重心放在诺和诺德的核心领域——代谢疾病与 ...

美国生物制药企业Metsera(MTSR.US)大涨超21.5%，报63.46美元。诺和诺德(NVO.US)跌近3%，报49.86 美元。 消息面上，诺和诺德对Metsera发起一项收购要约，提出每股56.5美元的全现金报价，对应企业价值约60 亿美元。辉瑞今年9月宣布，已同意以每股47.50美元现金收购Metsera，对应企业价值约49亿美元。若达 到特定研发目标，辉瑞还将额外支付每股22.50美元，使得交易总价值达到73亿美元。(格隆汇) ...

Novo Nordisk said on Thursday that it had adhered to all restrictions under the Pfizer merger agreement in its unsolicited offer for drugmaker Metsera , and that the value of its proposal far exceeded... ...